

1 **An *in-vitro* BBB-on-a-chip open model of human blood-brain barrier**
2 **enabling advanced optical imaging**

3
4
5 Mootaz Salman^{1,2}, Graham Marsh³, Ilja Küsters^{1,2}, Matthieu Delincé^{1,2}, Giuseppe Di
6 Caprio^{1,2}, Srigokul Upadhyayula^{1,2,4}, Giovanni de Nola^{1,2}, Ronan Hunt², Kazuka G.
7 Ohashi², Fumitaka Shimizu⁵, Yasuteru Sano⁵, Takashi Kanda⁵, Birgit Obermeier³, and
8 Tom Kirchhausen^{1,2,6*}

9
10 ¹Department of Cell Biology, Harvard Medical School, Boston, MA 02115, USA

11 ²Program in Cellular and Molecular Medicine, Boston Children's Hospital, Boston, MA
12 02115, USA

13 ³Biogen, 225 Binney Street, Cambridge, MA, 02142, USA

14 ⁴Present address: Department of Molecular and Cell Biology, University of California,
15 Berkeley, Berkeley, CA 94720, USA

16 ⁵Yamaguchi University Graduate School of Medicine, Minamikogushi, Ube, Yamaguchi,
17 7558505, Japan

18 ⁶Department of Pediatrics, Harvard Medical School, Boston, MA 02115, USA

19

20

21 *Corresponding author

22 kirchhausen@crystal.harvard.edu

23

24 **Key Words:** blood-brain barrier, capillary, microvessel, microfluidics, live cell imaging

25 **ABSTRACT**

26 **We describe here the design and implementation of an *in-vitro* BBB-on-a-chip open**
27 **model system capable of reconstituting the microenvironment of the blood brain barrier.**
28 **This system allows controlled unidirectional flow of nutrients and biologicals on the**
29 **lumen of the artificial microvessel. This BBB-on-a-chip is suitable for high resolution**
30 **electron microscopy and it is amenable for quantitative 3D live fluorescence imaging**
31 **using spinning confocal disk or lattice light sheet microscopy (LLSM) to follow, for**
32 **example the transcytosis across the BBB-like barrier of fluorescently-tagged biological,**
33 **viruses or nanoparticles.**

34 INTRODUCTION

35 The blood–brain barrier (BBB) is a unique and highly selective vascular interface that
36 separates the peripheral blood circulation from the neural tissue in order to maintain a
37 homeostatic microenvironment within the central nervous system (CNS) that allows the
38 neuronal network to function properly (Abbott et al., 2010; Park et al., 2019).

39

40 The BBB is a complex vascular structure with specialized endothelial cells as its core
41 element, surrounded by extracellular matrix (ECM) and supporting cells, such as
42 astrocytes and pericytes (Greene and Campbell, 2016). Brain microvascular endothelial
43 cells (BMVECs) that line the capillaries of the BBB are of crucial physiological
44 importance since they tightly control the molecular and cellular flux between the blood
45 and the brain, thereby regulating regional changes in nutrients and oxygen levels
46 (Daneman, 2012), maintaining brain energy levels (Bordone et al., 2019) and mediating
47 the local immune response in the CNS (Abbott et al., 2010). BMVECs differ from those
48 found in peripheral vasculature as they have no fenestration and exhibit restricted
49 paracellular passage for water and hydrophilic solutes due to the presence of a unique
50 array of tight junctions and adherens junctions between adjacent endothelial cells
51 (Greene and Campbell, 2016). Moreover, BMVECs have specialized transcellular
52 transport mechanisms ensuring only wanted substances being actively delivered to the
53 brain, and have shown to express a number of broad-spectrum efflux pumps on their
54 luminal surface which severely limit the uptake of lipophilic molecules, including small
55 molecule drugs, from the blood through the endothelium into the CNS. These
56 characteristic anatomical and functional features of the BBB determine its crucial
57 protective role for the CNS (Mahringer et al., 2011; Shawahna et al., 2011).

58

59 However, these highly selective barrier properties also extremely limit the therapeutic
60 efficacy of drugs and hinder the treatment of neurological diseases such as Alzheimer's
61 disease, multiple sclerosis, Parkinson's disease, HIV infection and brain tumors
62 (Pardridge, 2006). Beyond therapeutics' insufficient brain exposure, the BBB also plays
63 a major role in the underlying pathophysiology of many of these CNS disorders which
64 are usually associated with vascular hyperpermeability, transporter deficiencies, or an

65 increase in leukocyte adhesion molecules, resulting in an abnormal, uncontrolled
66 movement of cells and neurotoxins across the BBB vessel walls (Pardridge, 2006).

67
68 For studies of barrier function and dysfunction, *in vivo* models are of highest
69 physiological relevance since the BBB is embedded in its natural microenvironment.
70 These models are, however, limited in their throughput. Furthermore, animal models
71 may not predict BBB penetrance and efficacy of drugs in humans due to interspecies
72 differences in the molecular composition of the BBB (Uchida et al., 2011). Deciphering
73 the underlying molecular mechanisms and performing translatable real-time quantitative
74 assessments of drug transport across the BBB, such as screenings for BBB-penetrant
75 therapeutic antibodies, are therefore greatly limited in an *in vivo* setting. In contrast, *in*
76 *vitro* BBB models offer faster, yet simplified approaches for targeted drug screening as
77 well as for fundamental research, and importantly can be humanized to overcome
78 translatability issues.

79
80 Human BBB organoids provide a model that enables maintaining endothelial cells in
81 close juxtaposition. A limitation of this system, however, is that they essentially lack flow
82 since microvessel-like structures cannot be formed in organoids, rather endothelium-
83 lined spheres are generated which can negatively impact cellular viability (Urich et al.,
84 2013). Traditional two-dimensional (2D) *in vitro* BBB models such as the Transwell
85 system, in which endothelial cells are cultured on semi-permeable membranes, have
86 extensively been used for cell-based high-throughput screening assays and for studying
87 basic BBB characteristics such as barrier permeability and
88 transepithelial/transendothelial electrical resistance (TEER) (Abbott et al., 1992; Biegel
89 and Pachter, 1994; He et al., 2014). These simplified systems lack simulation of blood
90 flow conditions and have proved to insufficiently recapitulate *in vivo* phenotypes
91 including the expression of key junctional proteins (such as claudin-5) and transporters
92 (such as Glut-1 and insulin receptor) (Campisi et al., 2018; Wevers et al., 2018). To
93 overcome some of these limitations, several 3D microfluidic and organ-on-a-chip BBB
94 models have been developed enabling co-culture and fluid flow (Prabhakarpanidjan et
95 al., 2013; Herland et al., 2016; van Der Helm et al., 2016; Wevers et al., 2018; Oddo et

96 al., 2019; Park et al., 2019). Nevertheless, a number of these models exhibit other
97 limitations such as non-physiological rigid ECM substrates, failure to feature blood
98 vessel-like geometry and the lack of controlled flow that resembles the hemodynamic
99 forces which is known to be crucial for microvascular function (Herland et al., 2016).
100 Hence, there is an essential need for *in vitro* BBB models that better mimic the brain
101 microvessel environment including unidirectional flow, physiological shear stress,
102 absence of artificial membranes, and presence of the cylindrical geometry typical of
103 capillaries to facilitate the complex cell-cell interactions and physical ECM mechanics
104 known to be intrinsic to the *in vivo* BBB. In order to be capable of providing molecular
105 mechanistic insights, these models need to also be compatible with advanced imaging
106 and live 3D tracking of labeled molecules.

107
108 Along these lines, we describe here our efforts to develop and use an *in vitro* human
109 BBB-on-a-chip consisting of a 3D microfluidic model with a hollow brain-like microvessel
110 in which a continuous monolayer of cells can grow at the interphase between the lumen
111 and the underlying ECM. This system allows controlled unidirectional flow, within the
112 lumen of the artificial microvessel, of media including substrates of interest, for instance
113 drug candidate biologics. An important characteristic of our device is its open design
114 that also allows direct access of reagents from the surrounding space to the underlying
115 ECM. We demonstrate the utility of this open design of organ-on-a-chip model by
116 showing it is amenable for quantitative 3D live fluorescence imaging using spinning disk
117 confocal or lattice light sheet microscopy (LLSM) and for high resolution electron
118 microscopy. This model is set out to provide insights into molecular mechanisms
119 involved in the transcytosis of biologicals at extraordinary detail which will further
120 support the development of antibody-shuttle technologies across the human BBB.
121 Detailed imaging, for example, can be very useful to follow endo-lysosomal trafficking in
122 real-time, informing on fate of antibodies and viruses when entering endothelial cells,
123 thus informing on better designs of biologics and viral vectors that more efficiently
124 penetrate or inhibitors for the transcytosis of pathological viruses.

125 **MATERIALS AND METHODS**

126 **Cell culture**

127 Human brain derived microvascular endothelial cells (TY10 cell line) were isolated from
128 normal brain tissue from a patient with meningioma. Cells were immortalized with
129 retroviral vectors harboring a SV40 large T antigen gene that is engineered to drive
130 proliferation at 33 °C (Sano et al., 2010; Maeda et al., 2013; Sano et al., 2013) and have
131 been used to model the BBB in previous studies (Takeshita et al., 2014; Karassek et al.,
132 2015; Spampinato et al., 2015; Shimizu et al., 2017; Takeshita et al., 2017; Wevers et
133 al., 2018). Cells were cultured at 33 °C, 5% CO₂ in T75 flasks BioCoat (Corning,
134 354485, MA, USA). TY10 cells were used between passage 17–25 and cultured in
135 ScienCell complete endothelial cell medium (ScienCell, 1001, CA, USA). Cell
136 detachment was performed using Accutase® (Corning, 25-058-CI, MA, USA) when cells
137 were ~80–90% confluent before being seeded into the microfluidic devices. Cells were
138 routinely tested for mycoplasma contamination and found negative.

139

140 **TY10 stably expressing eGFP**

141 A lentiviral vector expressing a plasma membrane targeted eGFP (memGFP)
142 containing a chimera of the N-terminal 41 amino acids of human myristoylated alanine-
143 rich C-kinase substrate (MARCKS) fused to eGFP was made by co-transfection of a
144 plasmid harboring memGFP and Virapower Packaging Mix (Thermo Fisher, K497500,
145 MA, USA) into 293T cells. Culture media was harvested 72 h later, cellular debris
146 pelleted by low-speed centrifugation, and further clarified by 0.45 um filtration with
147 Millipore steriflip vacuum filters (EMD, SLHV033RS). The supernatant from the viral
148 preparation was added to a flask of TY10 cells during passaging (4 ml of viral
149 supernatant preparation mixed with 4 ml of cell suspension were added to a T25
150 Corning BioCoat flask) and allowed to incubate for 24 h at 33 °C before switching back
151 to the normal feeding schedule of every other day. The cells were sorted by flow
152 cytometry for eGFP positive cells after 10 days in culture and subsequently expanded
153 and maintained as described above.

154

155 **hmAb**

156 The recombinant monoclonal human IgG1 antibody (produced by Biogen) was
157 expressed in CHO cells and purified through Protein-A Affinity Chromatography. The
158 purified protein was fluorescently labeled with Alex Fluor™ 568 and 647 protein-labeling
159 kits (Thermo Fisher Scientific Cat# A10238 and A30009) to produce hmAb-AF568 and
160 hmAb-AF647 following the manufacturer's protocol.

161

162 **BBB-on-a-chip**

163 *Fabrication*

164 Molds for microfluidic channels with a width, height and length of 5 mm, 0.16 mm and
165 13 mm, respectively, were designed with AutoCAD software (AutoDesk Corp., CA,
166 USA) and produced by Outputcity (CAD/Art Services, Inc., Oregon, USA). Microfluidic
167 devices were subsequently produced by soft lithography; Sylgard 184 elastomer
168 Polydimethylsiloxane (PDMS) was mixed with curing agent (Sylgard 184 silicone
169 elastomer kit, Dow Corning, Midlands, USA), at a 5:1 ratio in a mixer including a 2 min
170 de-foaming step before pouring it onto the master silicon wafer designed by our lab and
171 spin-coating at 400 rpm for 40 seconds. The utilized speed yielded a PDMS film of 160
172 μm thickness that was degassed in a vacuum desiccator for 10 min and cured in an
173 oven at 65°C for 1h. The PDMS film was peeled off the master and placed in a plastic
174 petri dish at 65°C overnight to fully cure the PDMS. Incomplete curing of PDMS leaves
175 uncross-linked oligomers within the material that can leach out and contaminate the
176 culture medium (Halldorsson et al., 2015). So prior to assembly, pre-cut PDMS slabs
177 containing the embossed chip microstructures and 5x5 mm end pieces were pre-
178 cleaned by contact with Scotch tape and subjected to organic solvents to extract
179 uncured PDMS-oligomers (Lee et al., 2003). PDMS slabs were incubated in a sealed jar
180 on a rocker for 24h at room temperature (RT) in each of the following solvents and in
181 this order: Triethylamine, Toluene, Ethyl Acetate, and Acetone (Sigma). Organic solvent
182 was evaporated from the PDMS by incubation in a 100°C oven for 2h. Extracted PDMS
183 remains hydrophilic for prolonged times after activation and prevents the leaching of
184 uncured oligomers into the media (Lee et al., 2003; Kim and Herr, 2013). The PDMS
185 extraction step has significantly improved the success rate of final chips in the
186 downstream applications. The PDMS pieces of the chip were placed on a fluorinated

187 ethylene propylene (FEP) sheet and exposed to air plasma at 700mTorr, 30 W for 1.5
188 min using Plasma Etcher (Harrick Plasma), bonded to the PDMS end pieces before
189 punching 1mm holes for the tubing and plasma-bonding to the #1.5 glass coverslip that
190 was pre-cleaned by incubation in isopropyl alcohol, acetone and 0.5M KOH for 30 min
191 each in a sonication water bath, rinsing in dH₂O water and blown dry with filtered
192 nitrogen gas. We tested several glues to fix the Tygon microbore tubing, 0.010" x
193 0.030"OD (Cole-Parmer) on the chip and SLOW-CURE™ 30 min epoxy (Bob Smith
194 Industries; BSI206, CA, USA) resulted in the sturdiest connection and further allowed us
195 to remove air bubbles in the epoxy after mixing through centrifugation for 30 seconds at
196 14k g in a tabletop centrifuge. Following an overnight incubation at RT to fully cure the
197 epoxy, the chip was activated by air plasma treatment as above and further cleaned by
198 injecting sequentially 0.5 ml of each acetonitrile, purified water, 0.5M KOH and again
199 dH₂O. We functionalized the PDMS surface in a three-step process involving oxygen
200 plasma treatment, amino-silane conjugation and glutaraldehyde derivatization. To
201 functionalize both glass and PDMS surface with primary amine groups, the chips were
202 silanized by immediately adding 0.5 ml of a fresh 1% aqueous solution of 3-
203 (Ethoxydimethylsilyl) propylamine (Sigma, 588857) into the culturing chamber of the
204 chip and incubated for 15 min at RT before rinsing with twice with 1 ml dH₂O water.
205 Subsequently, the surfaces were further functionalized by filling the devices with 2.5%
206 glutaraldehyde (Electron Microscopy Services, 16200). After incubating for 15 min, the
207 devices were rinsed extensively with deionized water. The Schiff bases formed on
208 proteins after glutaraldehyde immobilization are stable without further reduction, as has
209 been demonstrated in surface-protein conjugation (Kim and Herr, 2013).

210

211 *Formation of lumen and collagen matrix*

212 A Pluronic F-127 (Sigma, P2443) passivated 100 µm acupuncture needle was inserted
213 from the outlet towards the inlet of the BBB-on-a-chip to provide the required scaffold for
214 the culturing matrix as indicated in Fig 1C. The selected size of the acupuncture needle
215 should prevent the leakage of unpolymerized collagen into the microfluidic channel of a
216 smaller diameter (80 µm). A hydrogel consisting of extracellular matrix (ECM) proteins
217 made of a final concentration of 7.0 mg/ml Type I rat tail collagen (Corning, 354249,

218 MA, USA) was used in all experiments. To make 200 μ L of hydrogel solution, 39 μ L of
219 Endothelial Cell Medium (ECM basal media with no FBS; 1001b, ScienCell, Carlsbad,
220 CA, USA), 1 μ L of a basic solution (1.0 N NaOH, Sigma) and 14 μ L of 10X Ham's F-12
221 (Thermo Fisher, 31765092, MA, USA) were added to 135 μ L of the collagen I.

222

223 We found that the collagen gel tended to delaminate from the PDMS culturing chamber
224 as soon as we started the flow, and so we enhanced the standard collagen matrix
225 protocol by adding Genipin[®] (Sigma, G4796). Genipin is a crosslinking agent that
226 covalently attaches to primary amino groups exposed on protein surfaces (Sung et al.,
227 1998). Furthermore, Genipin monomers form covalent intermolecular crosslinks that in
228 the case of a collagen matrix results in bridging adjacent fibers at points of contact (Yoo
229 et al., 2011; Chan et al., 2014). Thus, to achieve a stiff and resilient collagen matrix we
230 mixed collagen with Genipin prior pipetting it into the culturing chamber of the BBB-on-
231 a-chip. The solution of 135 μ L collagen, 39 μ L ECM, 14 μ L 10X Ham's F-12, 1 μ L 1N
232 NaOH and 1 μ L 20 mM Genipin was gently mixed and incubated on ice for a period of 5-
233 10 min to get rid of any air bubbles which might generate during the mixing step, before
234 being added to pre-chilled chips kept on ice for at least 15 min. The devices were
235 subsequently incubated at 37°C to allow gel formation of the collagen matrix. Genipin
236 improved the stability of the PDMS-collagen interaction such that delamination was
237 never observed for up to 12 days. After removal of the acupuncture needle, non-reacted
238 Genipin was quenched by covering the top of the collagen BBB-on-a-chip with PBS
239 containing 1 mM Tris pH 8.0 in PBS in addition to flowing the same solution through the
240 cylindrical lumen for 15 min at 1 μ L/min. Chips were then washed with 3 ml of PBS alone
241 (added to the top of collagen) and flow of PBS alone for 15 min at 1 μ L/min. Prior to cell
242 seeding (see below), a solution containing complete ECM medium was injected to the
243 lumen for 15 min at 1 μ L/min.

244

245 *Cell seeding*

246 To line the lumen with TY10 cells and generate a perfused microvessel-like structure,
247 two strategies were used to ensure uniform cell seeding. In the first strategy (cell
248 concentrator chip, Fig 2A), we designed a gravity-based microfluidic cell concentrator to

249 reach a sufficiently high density of cells for seeding of the collagen lumen using minimal
250 cell concentration. A PDMS chip whose single channel splits up into four microchannels
251 that merge again into a single channel after 5mm was used as bottom layer with a
252 central 2.5mm collection chamber. To securely fit a 25 mm long silicon tubing of OD
253 4mm / ID 2.5mm, a second PDMS layer with 4mm hole was bonded as a lid and the
254 tubing was fixated with epoxy glue. The inlet of the concentrator chip was connected via
255 tubing to a syringe pump and the outlet to the BBB-on-a-chip. TY10 cells were
256 resuspended to 0.1 million cells/ml and transferred into a 1ml syringe. The cells settled
257 by gravity within 15 min at the collection chamber on the bottom glass surface which
258 was passivated with 0.01 mg/ml Poly-D-Lysine-PEG to prevent the cells from sticking to
259 the glass. A plug compromised of an epoxy filled pipette tip was inserted into the central
260 tubing to prevent upwards flow before initiating the flow. Applying flow through the
261 microfluidic channel resulted in shear force that pushed the cell bolus into the tubing
262 leading to the culturing chamber of the BBB-on-a-chip.

263
264 In the second strategy a simplified procedure was implemented in order to enhance the
265 experimental turnover as illustrated in Fig 2B and its results section. In brief, TY10 cells
266 were harvested and resuspended to 1 million cells/ml. 900 µl of the cell solution was
267 then mixed with 100 µl solution of collagen IV (Sigma, C5533), fibronectin (Sigma,
268 F2518), and laminin (EMD Millipore, AG56P) at 5:1:1 concentration ratio before
269 transferred into a 1 ml syringe with BD Luer-Lok (BD, 309628, NJ, USA). The syringe
270 was then hanged vertically to allow cell settling by gravity for 10-15 min with no flow.
271 Cell seeding was initiated under flow for about 15-20 min at 1 µl/min. Cell seeding was
272 monitored by visual inspection using a microscope to observe the BBB-on-a-chip placed
273 inside a petri dish kept under sterile conditions.

274
275 After either procedure, chips were incubated at 37°C for a minimum of 4h before being
276 perfused with fresh ECM media via positive pumping to wash out the unattached cells.
277 The chips were maintained under continuous unidirectional flow at a rate of 1 µl/min in a
278 cell culture incubator at 37 °C, 5% CO₂. Confluent TY10 monolayers were formed

279 typically after 72h and the BBB-on-a-chip devices were used for subsequent analyses
280 following 7 days after seeding incubation in all experiments.

281

282 **Immunostaining**

283 The collagen samples including the lumen were fixed and permeabilized using BD
284 Cytofix/Cytoperm Kit (BD, 554714, NJ, USA) according to the manufacturer's protocol.
285 In brief, Cytofix was added to a 1 ml syringe and perfused through the microvessel at a
286 flow rate of 1 μ l/min for 30 min before changing to the Cytoperm buffer (diluted 1:10 in
287 PBS) for 1h at 1 μ l/min. The flow was then stopped and the BBB-on-a-chip placed on a
288 well of a six well plate in 2 ml of Cytoperm buffer (diluted 1:10 in PBS) overnight. The
289 microvessel was stained with AlexaFluor488 Phalloidin (Thermo, A12379, at 1:100
290 dilution) and NucBlue (Thermo, R37606, 1 drop/500 μ l) by perfusing the dyes in
291 Cytoperm buffer at 1 μ l/min through the microvessel for 1h, followed by washing with
292 0.1% BSA in PBS buffer for 4h at 1 μ l/min. Images were collected using a 3i spinning
293 disk microscope (40x water immersion objective) through the bottom glass slide.

294

295 **Barrier integrity assay**

296 Chips were washed with ECM culture medium (once with 1 ml added to the top of
297 collagen followed by a flow at 1 μ l/min for 15 min) to ensure proper flow profiles during
298 the subsequent barrier integrity assay. Next, all medium was aspirated from the chip
299 and 1 ml of medium without fluorescent compound using Gibco® FluoroBrite™
300 DMEM (Thermo Fisher, A1896701, MA, USA) was added. Medium containing 25 μ g/ml
301 of 10 kDa FITC-dextran (Sigma, FD10S) or hmAb-AF568 was added through the inlet at
302 a flow rate of 1 μ l/min for all the experiments. The inlet was connected to microvessels
303 with and without TY10 cells and image acquisition was started. Leakage of the
304 fluorescent substrate (dextran or hmAb) from the lumen of the microvessel into the
305 adjacent collagen matrix was imaged using a spinning disk confocal microscope with
306 40x water immersion objective. The fluorescence intensity profiles and ratios between
307 the fluorescent signal in the basal and apical region of the microvessel tube were
308 analyzed using MATLAB (MathWorks, MA, USA). Apparent permeability (P_{app}) was
309 used for quantifying diffusional permeability as described (Yuan et al., 2009). In brief,

310 Papp was calculated by analyzing total fluorescence intensity in the imaged 2D area of
311 the lumen and collagen and then applying $Papp = (1/\Delta l) (dl/dt)_0 (r/2)$, where Δl is the
312 increase in total fluorescence intensity upon adding labeled dextran or labeled hmAb to
313 the lumen, $(dl/dt)_0$ is the temporal initial rate of linear increase in intensity as the labeled
314 molecules diffuse out of the microvessel into the surrounding collagen matrix, and (r) is
315 the radius of the microvessel (100 μm for our BBB-on-a-chip). All experiments were
316 carried out at $n = 4-6$; exact numbers are mentioned per experiment in figure captions.
317 Graphs were plotted using GraphPad Prism 6 (GraphPad Software, San Diego, CA,
318 USA).

319

320 **Spinning disk confocal imaging**

321 Imaging was done using a Marianas spinning disk confocal microscope (3i, Denver,
322 Colorado) with the water immersion objective lens LD C-Apochromat 40x/1.1 (Carl
323 Zeiss, Jena, Germany). The images consisted of 512 x 512 pixels with a pixel size of ~
324 333 nm. The EMCCD camera settings (gain, speed, intensification, and exposure) and
325 laser power were maintained throughout the imaging experiments. Images were
326 acquired using SlideBook 6 (3i, Denver, Colorado) and data analysis carried out using
327 SlideBook 8 and custom made software using MATLAB 2017A (Natick, Massachusetts).
328 For the analysis of heat maps and Papp, ROIs were the entire original field of view.

329

330 **LLSM imaging**

331 A BBB-on-a-chip fabricated on 8*5-mm rectangular #1.5 glass coverslip was picked with
332 forceps, and placed in the sample bath of the 3D LLSM. The sample was imaged in a
333 time series in 3D using a dithered multi-Bessel lattice light-sheet by stepping the sample
334 stage at 200 nm intervals in the s-axis equivalent to ~104 nm translation in the z-axis.
335 Each 3D stack corresponded to a pre-deskewed volume of ~80 μm x 120 μm x 47 μm
336 (800 x 1200 x 451 pixels). The sample was excited with a 488-nm laser (~100mW
337 operating power with an illumination of ~77 μW at the back aperture), a 560-nm laser
338 (~100mW operating power with an illumination of ~176 μW at the back aperture) and a
339 642-nm laser (~100mW operating power with an illumination of ~121 μW at the back
340 aperture) to acquire 451 imaging planes, each exposed for ~44.1 ms and recorded with

341 two Hamamatsu ORCA-flash 4.0-V2 cameras; thus, each 3D image took ~60 s to
342 acquire. The inner and outer numerical apertures (NAs) of excitation were 0.513 and
343 0.55, respectively. The overall 3D volume of ~240um x 880um x 180um was obtained
344 by stitching together 165 (3 x 11 x 5) 3D stacks, with an overlap of 40 µm and 9 µm in
345 the y-axis and z-axis respectively.

346

347 **Transmission Electron Microscopy**

348 The collagen matrix including the lumen was washed 3 times with PBS and then fixed
349 by immersion in 5 ml of fixing solution (2.5% glutaraldehyde, 2% sucrose, 50 mM KCl,
350 2.5 mM MgCl₂, 2.5 mM CaCl₂ in 50 mM Cacodylate buffer pH 7.4) (Sigma) and kept at
351 4°C, overnight in the dark. Fixed collagen samples were washed 3 times with a solution
352 containing 50 mM PIPES pH 7.4 (Sigma, P6757) kept in ice and then they incubated for
353 2h in ice and in the dark in a freshly prepared staining solution (SSI) made of 1% OsO₄
354 (Electron Microscopy Sciences, 19190), 1.25% potassium hexacyanoferrate (II) (Sigma,
355 455989) and 100 mM PIPES pH 7.4. Samples were rinsed 3 times with ice-cold water
356 and incubated again for a second time for 30 min in ice and in the dark with a freshly
357 prepared staining solution II (SSII). SSII was prepared by 1:100 dilution of SSI in a
358 freshly prepared 1% thiocarbohydrazide (Electron Microscopy Sciences, 21900). Finally,
359 the samples were washed for 3 times with ice-cold H₂O and then incubated overnight in
360 the dark in 1% uranyl acetate (Electron Microscopy Sciences, 22400) at 4°C.

361

362 For the dehydration and embedding step, the fixed and stained samples were first
363 washed 3 times with ice cold water and then subjected to dehydration with a 20-50-70-
364 90-100% ethanol – 100% acetone dehydration series. Samples were then infiltrated
365 overnight, at 4°C with 50-50 acetone-Epon812 epoxy resin (Electron Microscopy
366 Sciences, 14120). Next day, the samples were washed 3 times with 100% Epon812 and
367 then kept in an oven for 36 h at 60°C. Sections of 60-70 nm were cut transversally to
368 the long axis of the lumen and imaged with a JEOL JEM 1200 EX TEM microscope with
369 a voltage of 80 KV and a nominal magnification of 15,000.

370

371 **Statistical analysis**

372 StatsDirect 3 (Liverpool, UK) was used for one-way ANOVA and student's t-test
373 analyses with Bonferroni *post-hoc* correction. Data were presented as mean±standard
374 error of the mean (S.E.M.) where (***) denotes a statistically significant difference with
375 $p < 0.0001$ and (ns) indicates a statistically non-significant difference.

376 **RESULTS AND DISCUSSION**

377 We designed an open design microfluidic chip to generate a 3D microphysiological
378 model of the human BBB readily accessible to optical imaging. The unique
379 characteristics of this novel BBB-on-a-chip are the open design of the cell culture
380 chamber and a cylindrical hollow lumen amenable to continuous flow within a casted gel
381 of extracellular matrix (ECM) components. The open system allows direct access of the
382 collagen matrix for efficient exchange of gases and medium in addition to readily access
383 to optical imaging while cells growing with continuous unidirectional flow at the
384 interphase between the casted gel and the lumen mimic the environment of a
385 microvessel.

386
387 Fig. 1A graphically summarizes the sequential steps used to build our BBB-on-a-chip
388 model. It is based on sequential bonding using soft lithography (Bischel et al., 2013) of
389 thin layers of optically clear PDMS on top on a glass microscope slide. The geometry
390 and dimensions of the BBB-on-a-chip were optimized for its use with three major
391 complementary forms of live 3D optical imaging, spinning disk confocal, lattice light
392 sheet microscopy (LLSM) and the recently developed variant, LLSM modified with
393 adaptive optics (AO-LLSM) (Gao et al., 2019). We chose to include access to LLSM and
394 AO-LLSM because these imaging modes have revolutionized fluorescence optical
395 microscopy providing volumetric imaging with unprecedented high spatial and temporal
396 precision with minimal bleaching and phototoxicity (Liu et al., 2018).

397 Spinning disk confocal microscopy is performed through the glass slide at the bottom of
398 the BBB-on-a-chip, while LLSM or AO-LLSM are carried out from the open top as
399 illustrated in Fig. 1B. The device is also suited for chemical fixation and the sample
400 preparation required for high-resolution electron microscopy visualization.

401
402 The consecutive stages used to generate the cylindrical hollow lumen within the casted
403 gel followed by seeding of endothelial cells on the wall of the lumen are depicted in Fig.
404 1C and described in detail in methods. It involved first placing an acupuncture needle
405 between the microfluidic inlet and outlets (Fig. 1C, 2) followed by casting a collagen
406 matrix (Fig. 1C, 3), gentle removal of the needle after collagen gelation (Fig. 1C, 4) and

407 ending with cell seeding under flow (Fig. 1C, 4). A Pluronic F-127 passivated 100 μm
408 acupuncture needle was inserted from the outlet towards the inlet to provide the
409 required scaffold for the culturing matrix. Collagen type I (7 mg/ml) has been used to
410 assemble the culturing scaffold. The chosen diameter of the needle enables the device
411 to recreate artificial microvessels where an endothelial monolayer is formed against a
412 collagen matrix and is stably maintained by surface tension and shear stress.

413
414 Cell seeding was done with two methods. The first one involved use of a cell-
415 concentrator chip designed and operated as indicated in Fig 2A. Cells in suspension
416 were placed on a pipette tip linked to the top of the cell-concentrator, allowed to settle
417 by gravity for 15 min to a cell density of ~ 0.1 million/ml, and cells then injected into the
418 BBB-on-a-chip with the aid of a syringe pump. Before activation of the syringe pump, we
419 replaced the pipette feeding cells with an epoxy-plugged pipette as a way to prevent
420 backflow. Afterwards the bolus with cells reached the BBB-on-a-chip, flow was then
421 stopped allowing cells to settle for 24 hrs so they could attach to the internal walls of the
422 cylindrical lumen of the BBB-on-a-chip. They were grown for 7 days under flow, at which
423 point they established a monolayer and hence were ready for the imaging experiments.
424 The second, and preferred cell seeding method (Fig. 2B), involved use of a 1 ml syringe
425 driven by a mechanical syringe pump. A solution containing ~ 900 μl of 1 million/ml
426 cells in medium mixed with 100 μl of a solution containing laminin 1, fibronectin and
427 collagen type IV, was placed in a vertically oriented syringe and cells allowed to settle
428 for ~ 10 -15 min. Afterwards, at flow of 1 $\mu\text{l}/\text{min}$ was applied for 10-15 min in order to
429 inject the cells into the BBB-on-a-chip; cells were then allowed to settle within the lumen
430 of the BBB-on-a-chip and attach to the internal walls of the lumen for 4 hrs at 37°C . As
431 with the first method, cells were then grown for 7 days at a flow rate of 1 $\mu\text{l}/\text{min}$, before
432 their use for imaging. This simpler cell seeding method is particularly advantageous for
433 cases in which the cellular supply might be limited such as when using primary cells or
434 iPSC-derived cells from patients. Extent of seeding was optically monitored with the aid
435 of an inverted microscope by direct inspection of the BBB-on-a-chip placed inside a
436 closed petri dish to ensure sterility.

437

438 In the brain, the basement membrane in contact with the endothelial cells of the BBB is
439 comprised of fibronectin, laminin (Aumailley et al., 2005) and collagen type IV
440 (Hartmann et al., 2007). Indeed, *in vitro* monolayers of endothelial cells grown on a
441 matrix containing fibronectin, laminin 1, and collagen type IV exhibit enhanced TEER,
442 suggesting a role for these molecules in promoting the formation of tight junctions
443 (Tilling et al., 1998; Tilling et al., 2002; Gautam et al., 2016). To mimic the physiological
444 BBB microenvironment and presumably also to enhance the seeding efficiency in the
445 BBB-on-a-chip, we injected before cell seeding a solution containing fibronectin and
446 laminin 1 for 30 min at 1 μ l/min. TY10 cells were allowed to settle for 24 hrs at 37°C
447 before starting the flow at 1 μ l/min.

448
449 One of the major challenges of developing physiologically relevant *in vitro* BBB models
450 is the availability of suitable brain-derived cells of endothelial origin and of human origin
451 in particular. Primary human brain endothelial cells or cells differentiated from induced
452 pluripotent stem cells (iPSC) derived from control or diseased patients are preferred for
453 *in vitro* BBB models. Use of primary cells is restricted to very low passage numbers to
454 prevent down-regulation of the unique features of the BBB (Reichel et al., 2003). More
455 general, the difficulties in collecting and purifying these cells can considerably limit their
456 use and reliability, as well as reproducibility ADD a ref specific for iPSCs (Bernas et al.,
457 2010). Immortalized brain-derived cell lines can have great advantages such as
458 accessibility and convenience of use especially for optimization purposes despite that
459 some of the available lines might not exhibit all BBB characteristics (Kuhline Sloan et
460 al., 2012; Eigenmann et al., 2013; Wong et al., 2013). Nonetheless, certain cell lines
461 may still exhibit the required properties for some pathophysiological and medicinal
462 applications in a fit-for-purpose approach. We therefore chose immortalized human
463 brain derived TY10 capillary endothelial cells that have been used to model the human
464 BBB in a number of previous studies (Takeshita et al., 2014; Spampinato et al., 2015;
465 Idris et al., 2018; Wevers et al., 2018).

466
467 TY10 cells are immortalized and proliferate at 33C, and stop growing and acquire a
468 phenotype of primary brain endothelial cells at 37C (Maeda et al., 2013). These cells

469 show a spindle-shaped morphology (Sano et al., 2013) and have well characterized
470 barrier-forming features of endothelial cells, expressing the majority of essential tight
471 junctional proteins, such as claudin-5, occludin, zonula occludens (ZO)-1 and ZO-2, as
472 well as expression of P-glycoprotein irrespective of passage number (Sano et al., 2010).
473 This is an important characteristic since shear stress is known to play a role in
474 regulating signaling cascades (Conway and Schwartz, 2012), enhancing the expression
475 of key genes associated with transporters and junctional proteins (Cucullo et al., 2011),
476 and plays a pivotal role in BBB regulation (Neuwelt et al., 2008; Neuwelt et al., 2011).

477
478 As depicted in the representative fluorescence microscopy image of a chemically fixed
479 sample stain for actin and DNA shown in Fig. 2C, TY10 cells grew as a monolayer at
480 the interphase between the cylindrical lumen and the collagen matrix in the BBB-on-a-
481 chip; grown for 7 days with constant flow at 1 μ l/min of media, they appeared elongated
482 along the flow axis, in agreement with previous findings (Ohashi and Sato, 2005; Aird,
483 2007). Further confirmation for the cell organization was obtained using TY10 cells
484 stably expressing soluble eGFP grown in a similar way and then imaged by live cell
485 fluorescence microscopy 3D imaging (Fig. 2D and related movie 1).

486 We further characterized, at the ultrastructural level, the TY10 cells grown under flow in
487 our BBB-on-a-chip as a way to detect presence of tight junctions between adjacent
488 TY10 cells grown at the lumen-collagen interphase by using transmission electron
489 microscopy (TEM) (Fig. 3). The representative images highlight presence of a narrow
490 gap between adjacent cells and occurrence of tight junctions. Similar images were
491 observed along most cell-cell contacts between TY10 cells imaged visualized in other
492 regions from this and other TEM sections.

493 TEER is frequently used to evaluate the integrity of the tight junctions and barrier
494 function of *in vitro* models of BBB. Use of this approach is not practical for our BBB-on-
495 a-chip model because the geometric constrains prevents us from positioning electrodes
496 on opposite sides of the endothelial monolayer between the cylindrical lumen and the
497 collagen matrix. To circumvent this limitation, we capitalized on our ability to use
498 fluorescence optical imaging with our device as a way to determine permeability

499 coefficient across the endothelial monolayer and hence establish the extent of the
500 barrier function of cells grown in the BBB-on-a-chip. Using spinning disk confocal
501 fluorescence microscopy, we determine the rate of transport of fluorescently tagged
502 humanized monoclonal hmAb-AF568 (Fig. 4A, C, D) or 10 kDa FITC-dextran (Fig. 4B)
503 across the lumen-matrix interphase in the absence or presence of cells. Unexpectedly,
504 in the absence of cells, we found retention of hmAb-AF568 at the lumen-matrix interface
505 (Fig. 4A, central fluorescence image). This retention appeared to be due to capture of
506 the antibody by unreacted Genipin (the stabilizing primary amine crosslinker used to
507 stabilize the collagen matrix, see Materials and Methods). Quenching the unreacted
508 reagent (see materials and methods) fully prevented the hmAb-AF568 capture (Fig. 4A,
509 right fluorescence image).

510

511 As shown by the time-dependent heat maps depicted in Figs. 4B and 4C, hmAb-AF568
512 and 10 kDa FITC-dextran freely diffused from the lumen towards the collagen matrix.
513 Their apparent permeability, determined as the flux through a given unit area under
514 gradient concentration (cm s^{-1}) were also similar (Fig. 4E) as expected for molecules
515 with comparable radius of gyration (1.86 nm and 5–6 nm, respectively) (Armstrong et
516 al., 2004; Hawe et al., 2011). In contrast, presence of the TY10 monolayer at the lumen-
517 matrix interphase significantly hindered the transport of hmAb-AF568 (Fig. 4D), with a
518 significantly lower apparent permeability (Fig. 4E). We conclude from these
519 observations that the TY10 cells grew as a relatively tight diffusion barrier in our BBB-on-
520 a-chip, in agreement with similar previous results obtained with these and other cells
521 using different *in vitro* human brain endothelial cell models (Eigenmann et al., 2013;
522 Wevers et al., 2018).

523 As a final proof-of-principle, we verified the large-scale 3D optical fluorescence imaging
524 capability of the BBB-on-a-chip, by using our LLSM set up (Fig. 5A) to visualize diffusing
525 fluorescently-tagged antibodies captured by beads that had been embedded in the
526 matrix; the antibody reached the beads upon diffusion from the lumen to the collagen.
527 The result from one such experiment, using 3 μm SPHERO™ goat anti-human IgG

528 coated polystyrene beads and hmAb-AF647 labeled antibodies is illustrated in Fig. 5B
529 (arrows).

530 These results provide a supporting evidence showing how the intrinsic open design of
531 our microfluidic BBB-on-a-chip device can be used to facilitate future studies of BBB
532 physiology at a subcellular level, particularly since cells can be grown under controlled
533 unidirectional flow conditions. The readily imaging accessibility of our BBB-on-a-chip is
534 particularly suited for investigations of molecular transport mechanisms involved in the
535 transcellular transport of biologicals, viruses or nanoparticles with extraordinary level of
536 detail. Although we exemplified here its implementation with a LLSM system, its design
537 also allows its use with AO-LLSM, which enables capture of high-resolution 3D movies
538 of collective behavior of cells in a multicellular environment (Ji, 2017; Gao et al., 2019).
539 Moreover, the open design of our BBB-on-a-chip facilitates use of chemical fixation of
540 the biological material located within the collagen matrix and permits ease use of
541 embedding procedures such as manipulations associated with conventional
542 transmission microscopy, with high resolution volumetric imaging using Focused Ion
543 Beam Scanning Electron Microscopy (FIB-SEM) and also with the newly developed
544 modality of expansion microscopy combined with LLSM (Ex-LLSM) (Xu et al., 2017;
545 Gao et al., 2019; Wassie et al., 2019).

546 **ACKNOWLEDGMENTS**

547 We thank Fang Qian and Benjamin Smith (Biogen) for generating the fluorescent hmAb
548 monoclonal antibody, G. Campbell Kaynor (Biogen) for providing the lentiviral construct
549 expressing memEGFP, Ramiro Massol and Chris Ehrenfels (Cellular Imaging Unit,
550 Biogen), Tegy John Vadakkan (T.K. Lab) for assistance with fluorescence microscopy
551 imaging and Robin Kleiman (Biogen) for critical feedback.

552

553 **CONFLICT OF INTEREST**

554

555 **AUTHOR CONTRIBUTIONS**

556 M.S., M.D., G.M. and T.K. conceived the project. M.S. and G.M. were involved in all
557 experiments. M.D., M.S., G.M., S.U. and T.K. designed the BBB-on-a-chip. R.H. built
558 BBB-on-a-chip devices under I.K. and M.S. supervision. G.M. and B.O. provided advice
559 on all aspects of the cell biology associated with this project. I.K. and M.S. performed
560 spinning disk confocal microscopy. K.G.H. performed lattice light sheet microscopy
561 under T.K.'s supervision. G.D.C. helped with data analysis. G. d. N. performed electron
562 microscopy. F.S., Y.S. and T.K. provided the parental TY10 cells and advised on cell
563 culture procedures. T.K. supervised the project. M.S, B.O. and T.K. wrote the
564 manuscript with comments from all authors.

565

566 **FUNDING**

567 This project was funded in part by a Biogen Sponsored Research Agreement to T.K and
568 NNF16OC0022166 Novo Nordisk Foundation / Danish Technical University grant to
569 T.K.

570

571 **DATA AVAILABILITY**

572 The datasets used and/or analyzed during the current study are available from the
573 corresponding author T.K. upon request.

574 **REFERENCES**

- 575 Abbott, N.J., Hughes, C., Revest, P.A., and Greenwood, J. (1992). Development and
576 characterisation of a rat brain capillary endothelial culture: towards an in vitro
577 blood-brain barrier. *Journal of cell science* 103(1), 23-37.
- 578 Abbott, N.J., Patabendige, A.A., Dolman, D.E., Yusof, S.R., and Begley, D.J. (2010).
579 Structure and function of the blood–brain barrier. *Neurobiology of disease* 37(1),
580 13-25.
- 581 Aird, W.C. (2007). Phenotypic heterogeneity of the endothelium: I. Structure, function,
582 and mechanisms. *Circulation research* 100(2), 158-173.
- 583 Armstrong, J.K., Wenby, R.B., Meiselman, H.J., and Fisher, T.C. (2004). The
584 hydrodynamic radii of macromolecules and their effect on red blood cell
585 aggregation. *Biophysical journal* 87(6), 4259-4270.
- 586 Aumailley, M., Bruckner-Tuderman, L., Carter, W., Deutzmann, R., Edgar, D., Ekblom,
587 P., et al. (2005). A simplified nomenclature for laminin. *Matrix Biol* 24, 326-332.
- 588 Bernas, M.J., Cardoso, F.L., Daley, S.K., Weinand, M.E., Campos, A.R., Ferreira,
589 A.J.G., et al. (2010). Establishment of primary cultures of human brain
590 microvascular endothelial cells to provide an in vitro cellular model of the blood-
591 brain barrier. *Nature protocols* 5(7), 1265.
- 592 Biegel, D., and Pachter, J.S. (1994). Growth of brain microvessel endothelial cells on
593 collagen gels: applications to the study of blood-brain barrier physiology and
594 CNS inflammation. *In Vitro Cellular & Developmental Biology-Animal* 30(9), 581-
595 588.
- 596 Bischel, L.L., Young, E.W., Mader, B.R., and Beebe, D.J. (2013). Tubeless microfluidic
597 angiogenesis assay with three-dimensional endothelial-lined microvessels.
598 *Biomaterials* 34(5), 1471-1477.
- 599 Bordone, M.P., Salman, M.M., Titus, H.E., Amini, E., Andersen, J.V., Chakraborti, B., et
600 al. (2019). The energetic brain—A review from students to students. *Journal of*
601 *neurochemistry* 151(2), 139-165.
- 602 Campisi, M., Shin, Y., Osaki, T., Hajal, C., Chiono, V., and Kamm, R.D. (2018). 3D self-
603 organized microvascular model of the human blood-brain barrier with endothelial
604 cells, pericytes and astrocytes. *Biomaterials* 180, 117-129.
- 605 Chan, K.L., Khankhel, A.H., Thompson, R.L., Coisman, B.J., Wong, K.H., Truslow, J.G.,
606 et al. (2014). Crosslinking of collagen scaffolds promotes blood and lymphatic
607 vascular stability. *Journal of Biomedical Materials Research Part A* 102(9), 3186-
608 3195.
- 609 Conway, D., and Schwartz, M.A. (2012). Lessons from the endothelial junctional
610 mechanosensory complex. *F1000 biology reports* 4.
- 611 Cucullo, L., Hossain, M., Puvenna, V., Marchi, N., and Janigro, D. (2011). The role of
612 shear stress in Blood-Brain Barrier endothelial physiology. *BMC neuroscience*
613 12(1), 40.
- 614 Daneman, R. (2012). The blood–brain barrier in health and disease. *Annals of*
615 *neurology* 72(5), 648-672.
- 616 Eigenmann, D.E., Xue, G., Kim, K.S., Moses, A.V., Hamburger, M., and Oufir, M.
617 (2013). Comparative study of four immortalized human brain capillary endothelial
618 cell lines, hCMEC/D3, hBMEC, TY10, and BB19, and optimization of culture

- 619 conditions, for an in vitro blood–brain barrier model for drug permeability studies.
620 *Fluids and Barriers of the CNS* 10(1), 33.
- 621 Gao, R., Asano, S.M., Upadhyayula, S., Pisarev, I., Milkie, D.E., Liu, T.-L., et al. (2019).
622 Cortical column and whole-brain imaging with molecular contrast and nanoscale
623 resolution. *Science* 363(6424), eaau8302.
- 624 Gautam, J., Zhang, X., and Yao, Y. (2016). The role of pericytic laminin in blood brain
625 barrier integrity maintenance. *Scientific reports* 6(1), 1-13.
- 626 Greene, C., and Campbell, M. (2016). Tight junction modulation of the blood brain
627 barrier: CNS delivery of small molecules. *Tissue barriers* 4(1), e1138017.
- 628 Halldorsson, S., Lucumi, E., Gómez-Sjöberg, R., and Fleming, R.M. (2015). Advantages
629 and challenges of microfluidic cell culture in polydimethylsiloxane devices.
630 *Biosensors and Bioelectronics* 63, 218-231.
- 631 Hartmann, C., Zozulya, A., Wegener, J., and Galla, H.-J. (2007). The impact of glia-
632 derived extracellular matrices on the barrier function of cerebral endothelial cells:
633 an in vitro study. *Experimental cell research* 313(7), 1318-1325.
- 634 Hawe, A., Hulse, W.L., Jiskoot, W., and Forbes, R.T. (2011). Taylor dispersion analysis
635 compared to dynamic light scattering for the size analysis of therapeutic peptides
636 and proteins and their aggregates. *Pharmaceutical research* 28(9), 2302-2310.
- 637 He, Y., Yao, Y., Tsirka, S.E., and Cao, Y. (2014). Cell-culture models of the blood–brain
638 barrier. *Stroke* 45(8), 2514-2526.
- 639 Herland, A., van der Meer, A.D., FitzGerald, E.A., Park, T.-E., Sleebom, J.J., and
640 Ingber, D.E. (2016). Distinct contributions of astrocytes and pericytes to
641 neuroinflammation identified in a 3D human blood-brain barrier on a chip. *PLoS*
642 *One* 11(3).
- 643 Idris, F., Muharram, S.H., Zaini, Z., and Diah, S. (2018). Establishment of murine in vitro
644 blood-brain barrier models using immortalized cell lines: co-cultures of brain
645 endothelial cells, astrocytes, and neurons. *bioRxiv*, 435990.
- 646 Ji, N. (2017). Adaptive optical fluorescence microscopy. *Nature methods* 14(4), 374.
- 647 Karassek, S., Starost, L., Solbach, J., Greune, L., Sano, Y., Kanda, T., et al. (2015).
648 Pertussis toxin exploits specific host cell signaling pathways for promoting
649 invasion and translocation of Escherichia coli K1 RS218 in human brain-derived
650 microvascular endothelial cells. *Journal of Biological Chemistry* 290(41), 24835-
651 24843.
- 652 Kim, D., and Herr, A.E. (2013). Protein immobilization techniques for microfluidic
653 assays. *Biomicrofluidics* 7(4), 041501.
- 654 Kuhnline Sloan, C.D., Nandi, P., Linz, T.H., Aldrich, J.V., Audus, K.L., and Lunte, S.M.
655 (2012). Analytical and biological methods for probing the blood-brain barrier.
656 *Annual Review of Analytical Chemistry* 5, 505-531.
- 657 Lee, J.N., Park, C., and Whitesides, G.M. (2003). Solvent compatibility of poly
658 (dimethylsiloxane)-based microfluidic devices. *Analytical chemistry* 75(23), 6544-
659 6554.
- 660 Liu, T.-I., Upadhyayula, S., Milkie, D.E., Singh, V., Wang, K., Swinburne, I.A., et al.
661 (2018). Observing the cell in its native state: Imaging subcellular dynamics in
662 multicellular organisms. *Science* 360(6386), eaaq1392.

- 663 Maeda, T., Sano, Y., Abe, M., Shimizu, F., Kashiwamura, Y., Ohtsuki, S., et al. (2013).
664 Establishment and characterization of spinal cord microvascular endothelial cell
665 lines. *Clinical and Experimental Neuroimmunology* 4(3), 326-338.
- 666 Mahringer, A., Ott, M., Reimold, I., Reichel, V., and Fricker, G. (2011). The ABC of the
667 blood-brain barrier-regulation of drug efflux pumps. *Current pharmaceutical*
668 *design* 17(26), 2762-2770.
- 669 Neuwelt, E., Abbott, N.J., Abrey, L., Banks, W.A., Blakley, B., Davis, T., et al. (2008).
670 Strategies to advance translational research into brain barriers. *The Lancet*
671 *Neurology* 7(1), 84-96.
- 672 Neuwelt, E.A., Bauer, B., Fahlke, C., Fricker, G., Iadecola, C., Janigro, D., et al. (2011).
673 Engaging neuroscience to advance translational research in brain barrier biology.
674 *Nature Reviews Neuroscience* 12(3), 169-182.
- 675 Oddo, A., Peng, B., Tong, Z., Wei, Y., Tong, W.Y., Thissen, H., et al. (2019). Advances
676 in microfluidic blood–brain barrier (BBB) models. *Trends in biotechnology*.
- 677 Ohashi, T., and Sato, M. (2005). Remodeling of vascular endothelial cells exposed to
678 fluid shear stress: experimental and numerical approach. *Fluid dynamics*
679 *research* 37(1-2), 40.
- 680 Pardridge, W.M. (2006). Molecular Trojan horses for blood–brain barrier drug delivery.
681 *Current opinion in pharmacology* 6(5), 494-500.
- 682 Park, T.-E., Mustafaoglu, N., Herland, A., Hasselkus, R., Mannix, R., FitzGerald, E.A., et
683 al. (2019). Hypoxia-enhanced Blood-Brain Barrier Chip recapitulates human
684 barrier function and shuttling of drugs and antibodies. *Nature communications*
685 10(1), 1-12.
- 686 Prabhakarandian, B., Shen, M.-C., Nichols, J.B., Mills, I.R., Sidoryk-Wegrzynowicz, M.,
687 Aschner, M., et al. (2013). SyM-BBB: a microfluidic blood brain barrier model.
688 *Lab on a Chip* 13(6), 1093-1101.
- 689 Reichel, A., Begley, D.J., and Abbott, N.J. (2003). "An overview of in vitro techniques for
690 blood-brain barrier studies," in *The Blood-Brain Barrier*. Springer), 307-324.
- 691 Sano, Y., Kashiwamura, Y., Abe, M., Dieu, L.H., Huwyler, J., Shimizu, F., et al. (2013).
692 Stable human brain microvascular endothelial cell line retaining its barrier-
693 specific nature independent of the passage number. *Clinical and experimental*
694 *neuroimmunology* 4(1), 92-103.
- 695 Sano, Y., Shimizu, F., Abe, M., Maeda, T., Kashiwamura, Y., Ohtsuki, S., et al. (2010).
696 Establishment of a new conditionally immortalized human brain microvascular
697 endothelial cell line retaining an in vivo blood–brain barrier function. *Journal of*
698 *cellular physiology* 225(2), 519-528.
- 699 Shawahna, R., Uchida, Y., Decleves, X., Ohtsuki, S., Yousif, S., Dauchy, S., et al.
700 (2011). Transcriptomic and quantitative proteomic analysis of transporters and
701 drug metabolizing enzymes in freshly isolated human brain microvessels.
702 *Molecular pharmaceuticals* 8(4), 1332-1341.
- 703 Shimizu, F., Schaller, K.L., Owens, G.P., Coteleur, A.C., Kellner, D., Takeshita, Y., et al.
704 (2017). Glucose-regulated protein 78 autoantibody associates with blood-brain
705 barrier disruption in neuromyelitis optica. *Science translational medicine* 9(397).
- 706 Spampinato, S.F., Obermeier, B., Coteleur, A., Love, A., Takeshita, Y., Sano, Y., et al.
707 (2015). Sphingosine 1 phosphate at the blood brain barrier: can the modulation

- 708 of s1p receptor 1 influence the response of endothelial cells and astrocytes to
709 inflammatory stimuli? *PloS one* 10(7).
- 710 Sung, H.W., Huang, R.N., Huang, L.L., Tsai, C.C., and Chiu, C.T. (1998). Feasibility
711 study of a natural crosslinking reagent for biological tissue fixation. *Journal of*
712 *Biomedical Materials Research: An Official Journal of The Society for*
713 *Biomaterials, The Japanese Society for Biomaterials, and the Australian Society*
714 *for Biomaterials* 42(4), 560-567.
- 715 Takeshita, Y., Obermeier, B., Cotleur, A., Sano, Y., Kanda, T., and Ransohoff, R.M.
716 (2014). An in vitro blood–brain barrier model combining shear stress and
717 endothelial cell/astrocyte co-culture. *Journal of neuroscience methods* 232, 165-
718 172.
- 719 Takeshita, Y., Obermeier, B., Cotleur, A.C., Spampinato, S.F., Shimizu, F., Yamamoto,
720 E., et al. (2017). Effects of neuromyelitis optica–IgG at the blood–brain barrier in
721 vitro. *Neurology-Neuroimmunology Neuroinflammation* 4(1), e311.
- 722 Tilling, T., Engelbertz, C., Decker, S., Korte, D., Hüwel, S., and Galla, H.-J. (2002).
723 Expression and adhesive properties of basement membrane proteins in cerebral
724 capillary endothelial cell cultures. *Cell and tissue research* 310(1), 19-29.
- 725 Tilling, T., Korte, D., Hoheisel, D., and Galla, H.J. (1998). Basement membrane proteins
726 influence brain capillary endothelial barrier function in vitro. *Journal of*
727 *neurochemistry* 71(3), 1151-1157.
- 728 Uchida, Y., Ohtsuki, S., Katsukura, Y., Ikeda, C., Suzuki, T., Kamiie, J., et al. (2011).
729 Quantitative targeted absolute proteomics of human blood–brain barrier
730 transporters and receptors. *Journal of neurochemistry* 117(2), 333-345.
- 731 Urich, E., Patsch, C., Aigner, S., Graf, M., Iacone, R., and Freskgård, P.-O. (2013).
732 Multicellular self-assembled spheroidal model of the blood brain barrier. *Scientific*
733 *reports* 3, 1500.
- 734 van Der Helm, M.W., Van Der Meer, A.D., Eijkel, J.C., van den Berg, A., and Segerink,
735 L.I. (2016). Microfluidic organ-on-chip technology for blood-brain barrier
736 research. *Tissue barriers* 4(1), e1142493.
- 737 Wassie, A.T., Zhao, Y., and Boyden, E.S. (2019). Expansion microscopy: principles and
738 uses in biological research. *Nature methods* 16(1), 33-41.
- 739 Wevers, N.R., Kasi, D.G., Gray, T., Wilschut, K.J., Smith, B., Van Vught, R., et al.
740 (2018). A perfused human blood–brain barrier on-a-chip for high-throughput
741 assessment of barrier function and antibody transport. *Fluids and Barriers of the*
742 *CNS* 15(1), 23.
- 743 Wong, A., Ye, M., Levy, A., Rothstein, J., Bergles, D., and Searson, P.C. (2013). The
744 blood-brain barrier: an engineering perspective. *Frontiers in neuroengineering* 6,
745 7.
- 746 Xu, C.S., Hayworth, K.J., Lu, Z., Grob, P., Hassan, A.M., Garcia-Cerdan, J.G., et al.
747 (2017). Enhanced FIB-SEM systems for large-volume 3D imaging. *Elife* 6,
748 e25916.
- 749 Yoo, J.S., Kim, Y.J., Kim, S.H., and Choi, S.H. (2011). Study on genipin: a new
750 alternative natural crosslinking agent for fixing heterograft tissue. *The Korean*
751 *journal of thoracic and cardiovascular surgery* 44(3), 197.

752 Yuan, W., Lv, Y., Zeng, M., and Fu, B.M. (2009). Non-invasive measurement of solute
753 permeability in cerebral microvessels of the rat. *Microvascular research* 77(2),
754 166-173.
755

756 **FIGURE LEGENDS**

757 **Figure 1. Fabrication of the BBB-on-a-chip.**

758 **(A)** Schematic representation of the sequential steps used to fabricate the BBB-on-a-
759 chip. The open design permits direct access of aerated medium from the top to the
760 collagen containing embedded cells while at the same time allowing flow of medium
761 along the tubular channel with endothelial cells surrounding the boundary between the
762 lumen of the artificial microvessel and the collagen.

763 **(B)** Arrangement of the BBB-on-a-chip within the available optical path between the
764 illumination and detection objectives of the lattice light sheet microscope. A sample
765 holder is used to place the BBB-on-a-chip under the LLSM objectives and to facilitate
766 fine adjustments of its position.

767 **(C)** Steps used to create the artificial microvessel. An acupuncture needle of 100 μm
768 diameter is placed between the inlet and outlet. After the collagen gelled, the needle
769 was pulled, resulting in a void channel in which endothelial cells are seeded. The cross
770 section on the bottom shows the final disposition of the endothelial cells (green) which
771 line the inner surface of the collagen lumen, representing the artificial BBB microvessel.

772

773 **Figure 2. Cell seeding procedures and formation of a BBB microvessel using**
774 **TY10 cells**

775 **(A)** Cell seeding, 1st method. Representation of the steps used to increase the cell
776 concentration before injection into the BBB-on-a-chip. Cells are allowed to settle by
777 gravity (left and central panels) in the cell seeder and then injected as a bolus into the
778 BBB-on-a-chip. Prior to injection, the chamber is capped with a plugged pipette tip
779 (central panel).

780 **(B)** Cell seeding, 2nd method. Representation of the steps used to inject cells into the
781 BBB-on-a-chip in a more controlled and uniform manner compared to the 1st method.
782 Cells are allowed to settle at the bottom of a syringe, and are then delivered into the
783 BBB-on-a-chip at constant flow controlled by a syringe pump.

784 **(C)** Representative image of a chemically fixed sample of TY10 cells after they were
785 grown in the BBB-on-a-chip with medium flowing at 1 μl / min for 7 days. Volumetric
786 image was obtained using a spinning disk confocal microscope. Maximum z-projection

787 is shown for a sample stained with DAPI (nuclei, blue) and an antibody specific for actin
788 (green). Scale bar, 100 μm .

789 **(D)** Representative volumetric image of a live sample of TY10-eGFP cells expressing
790 membrane bound eGFP obtained using spinning disk confocal microscopy. The image
791 highlights the organization of the cells as a monolayer at the boundary between the
792 lumen of the artificial microvessel and the collagen scaffold. The cells on the bottom
793 illustrate cells growing between the glass slide and the lumen. Panels are rotated 90-
794 degrees from each other. Scale bar, 50 μm . See associated Movie 1.

795

796 **Figure 3. Transmission electron microscopy highlighting the appearance of**
797 **junctions between TY10 endothelial cells within the BBB-on-a-chip.**

798 The upper left panel shows a schematic cross section of the BBB-on-a-chip highlighting
799 the location of the monolayer of TY10 endothelial cells at the interface between the
800 lumen of the microvessel and the collagen. The representative images in the bottom
801 panels derive from junctions between opposite ends of adjacent cells. The yellow
802 arrows highlight electron-density characteristic of tight junctions. Scale bars with
803 corresponding magnifications are indicated.

804

805 **Figure 4. TY10 cells establish a functional barrier in the BBB-on-a-chip.**

806 **(A)** The left panel is a schematic representation of the experimental setup used to
807 determine the apparent permeability of fluorescent solutes diffusing between the lumen
808 of the artificial microvessel and the collagen in the absence and presence of TY10 cells.
809 The boxed numbered areas represent typical regions imaged using spinning disk
810 confocal microscopy. The fluorescent images are of hmAb-AF568 (red) applied at
811 constant flow (1 μl /min) for 20 min in the absence (left and central panels) and
812 presence (right panel) of 1 mM TRIS in addition to Genipin (a chemical crosslinker)
813 added to stabilize the collagen matrix (see Methods). Genipin followed by 1 mM TRIS
814 treatment dramatically decreased the non-specific retention of the antibody by the
815 collagen.

816 **(B-D)** Heat map representation of the fluorescence intensity of 10 kDa FITC-Dextran **(B)**
817 or antibody hmAb-AF568 **(C)** from the lumen through the collagen as a function of time

818 obtained at a flow of 1 μ l /min. The significant decrease in the amount of antibody that
819 passes through the endothelial cell layer is highlighted in panel (D), demonstrating that
820 TY10 cells form a functional barrier in the BBB-on-a-chip. See associated Movies 2, 3
821 and 4.

822 (E) Apparent permeability of data obtained from experiments carried as described in (B-
823 D) for 10 kDa FITC-Dextran or hmAb-AF588 diffusion across the boundary between the
824 lumen and collagen without cells (n=6 each), and for hmAb-AF588 diffusion with TY10
825 cells (n=4). Kruskal-Wallis with Conover-Inman post hoc tests were used to identify
826 significant differences between samples. Error bars indicate S.E. M.; *** $p \leq 0.001$, ns:
827 non-significant.

828

829 **Figure 5. Visualizing IgG antibody diffusion in the BBB-on-a-chip device using**
830 **LLSM.**

831 (A) Schematic representation of the volumetric imaging strategy used to visualize the
832 lumen of the microvessel and surrounding volume within the BBB-on-a-chip using
833 LLSM. The cubes represent the adjacent regions imaged by serial scanning of the
834 sample using a distance of 100 nm between planes.

835 (B) Selected planes corresponding to the volumetric imaging obtained using LLSM of a
836 sample containing 3 μ m SPHERO™ Goat anti-Human IgG coated polystyrene beads
837 embedded in the collagen matrix. Before imaging, a solution containing hmAb-AF647
838 was perfused at 1 μ l / min for 20 min. The fluorescent spots marked by arrows in the
839 selected planes located 7.7, 13.7 and 16.2 μ m apart correspond to the signal of hmAb-
840 AF647 captured by the beads within the collagen matrix. Scale bar, 30 μ m.

841

842 **Movie 1. Live cell imaging of a BBB-on-a-chip.** 3D rendition of a live sample of TY10-
843 eGFP cells expressing membrane bound eGFP grown as a monolayer at the boundary
844 between the lumen of the artificial microvessel and the collagen scaffold within the BBB-
845 on-a-chip. The volumetric image was obtained using spinning disk confocal microscopy.

846

847 **Movie 2. Absence of a functional barrier between the lumen and the collagen**
848 **matrix of the BBB-on-a-chip.** Time series of the fluorescence intensity presented as a

849 heat map of 10 kDa FITC-Dextran diffusing from the lumen through the collagen as a
850 function of time obtained at a flow of 1 μ l /min. Data was obtained in the absence of a
851 cell monolayer at the boundary between the lumen of the artificial microvessel and the
852 collagen scaffold within the BBB-on-a-chip.

853


854 **Movie 3 TY10 cells establish a functional barrier in the BBB-on-a-chip.** Time series
855 of the fluorescence intensity presented as a heat map of antibody hmAb-AF568
856 diffusing from the lumen through the collagen as a function of time obtained at a flow of
857 1 μ l /min. Data was obtained in the presence of a monolayer of TY10 cells at the
858 boundary between the lumen of the artificial microvessel and the collagen scaffold
859 within the BBB-on-a-chip.

860

861 **Movie 4. TY10 cells establish a functional barrier in the BBB-on-a-chip.** Time
862 series of the fluorescence intensity presented as a heat map of antibody hmAb-AF568
863 diffusing from the lumen through the collagen as a function of time obtained at a flow of
864 1 μ l /min. Data is a second example obtained in the presence of a monolayer of TY10
865 cells at the boundary between the lumen of the artificial microvessel and the collagen
866 scaffold within the BBB-on-a-chip.

A

1. plasma bonded layering of PDMS




screw

tubing, screw


2. punch holes




3. bond to glass coverslip



4. connect tubing and glue



5. BBB-on-a-Chip

**B**

LLSM configuration for BBB-on-a-Chip

illumination objective

detection objective

wide-field objective

BBB on a chip

sample holder





Figure 1






Figure 1

A cell seeding, 1° method



B BBB-on a-Chip and cell seeding, 2° method






Figure 2




Figure 3








Figure 4




Figure 5